Delivering end-to-end services to ensure patients in the UK get efficient access to pharmaceutical therapeutics and diagnostics.


The recent discussions around the Ten Year Plan for the NHS and the potential merging of Integrated Care Boards present unique opportunities for the rare disease community. The shift from sickness to prevention, especially in the context of early diagnosis and treatment, can have a significant impact on patients, families, and healthcare systems. As we navigate these changes, it's crucial that rare diseases are not forgotten and are included in the broader healthcare discussions. Looking forward to seeing how we can continue to advocate for rare diseases in the evolving healthcare landscape. With Rosie Lindup, Senior Government Affairs Manager, BioIndustry Association (BIA), Deborah Richards, Rare Diseases GM, UK&I Alexion Pharmaceuticals, Inc. and Steven Ferguson, Director, Value and Access, IQVIA.
Delivering end-to-end services to ensure patients in the UK get efficient access to pharmaceutical therapeutics and diagnostics.